Di Wu

TL;DR: The largest sample size allows, for the first time, a comparison of primary melanoma stage and patterns of metastases across anatomical sites and suggests that clinical trials involving mucosal melanomas and the administration of systemic therapy can be applied equally to mucosa melanomas regardless of their primary anatomic site.

TL;DR: Pembrolizumab was well tolerated and provided clinically meaningful antitumor activity as second-line therapy in Chinese patients with advanced melanoma and two deaths occurred that were unrelated to treatment.

TL;DR: Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma refractory to standard therapy in what is the largest prospective anti-PD-1 clinical study in advanced melanoma with predominantly acral and mucosal subtypes.

TL;DR: The 2015 edition of the Chinese Guidelines on the Diagnosis and Treatment of Melanoma was finalized after repeated and wide consultations with multidisciplinary experts and updated and added with much new information, with an attempt to provide the up-todated and reliable instructions on clinical practices based recent scientific evidences.

TL;DR: Substantial clinicopathological and survival heterogeneities exist across different primary sites in the AM population, and Sole melanoma has worse prognosis compared with palm and nail bed subtypes.